



Investor News 2007

The news contents can be obtained from our website www.investor.bayer.com

- December 10, 2007 **VTE Prevention After Major Orthopaedic Surgery:
Three Pivotal Phase III Trials Show Superior Efficacy of Rivaroxaban over Standard of Care with Enoxaparin**
- Consistent results across three RECORD trials involving nearly 10,000 patients
- Venous thromboembolism considered the most frequent and potentially fatal complication following major orthopaedic surgery
- No evidence of liver signal attributable to rivaroxaban has been seen
- December 08, 2007 **VTE Prevention After Hip Replacement Surgery:
Pivotal Phase III Data Show Superior Efficacy of Rivaroxaban over Enoxaparin**
Head-to-Head Study Demonstrates Similar and Low Rate of Bleeding for Both Drugs
- December 03, 2007 **Bayer Schering Pharma paves the way to the next important oral contraceptive milestone**
- November 26, 2007 **Bayer CropScience, Mertec and M.S. Technologies to co-develop new soybean trait products**
Joint collaboration will bring alternative herbicide tolerant systems and more choice for farmers in weed management
- November 19, 2007 **Nexavar® First FDA-Approved Drug Therapy for Liver Cancer**
Only Systemic Therapy Proven to Significantly Improve Overall Survival in Patients with Liver Cancer
- November 09, 2007 **New Phase III Trial Results for Rivaroxaban to be Presented at the 49th Annual Meeting of the American Society of Hematology**
Endpoints Met for RECORD1 and RECORD2 Trials in Total Hip Replacement Surgery
- November 06, 2007 **Fall Financial News Conference in Leverkusen
Bayer expects a record year in 2007**
- Third-quarter sales grow 4.5 percent to EUR 7,793 million
- EBITDA before special items advances 6.9 percent to EUR 1,559 million
- EBIT before special items climbs 23.9 percent to EUR 953 million
- Group net income of EUR 1,175 million after one-time positive tax effect
- November 05, 2007 **Bayer Temporarily Suspends Global Trasylol® Marketing**
- October 31, 2007 **Prevention of Venous Thromboembolism after Major Orthopedic Surgery:
Bayer HealthCare Submits Rivaroxaban for European Approval**
Data Package for Rivaroxaban Involves Nearly 10,000 Patients in Three Phase III Trials
- October 30, 2007 **Bayer sells Hennecke to Adcuram**
- October 30, 2007 **Nexavar® Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe**
Only Systemic Therapy Shown to Significantly Extend Survival in Patients with Most Common Form of Liver Cancer

October 29, 2007 Therapy of multiple sclerosis
BEYOND study: Results do not support regulatory filing for Betaferon® 500 mcg
- Betaferon® 250 mcg is optimal Betaferon® dose based on high efficacy and excellent tolerability
- Study unable to show superiority of Betaferon® 500 mcg compared to Betaferon 250® mcg and Copaxone®

October 26, 2007 **Court rules in favor of Bayer over Avelox® patents**

October 26, 2007 **Bayer MaterialScience raises prices for polycarbonates**

October 25, 2007 **Bayer Issues Additional Guidance to Physicians on Trasylol®**

October 23, 2007 B-cell Chronic Lymphocytic Leukemia (B-CLL):
MabCampath® Receives Positive Opinion from European Committee for Medicinal Products for Human Use

October 15, 2007 New top-line efficacy data presented from phase II trial of Alemtuzumab in multiple sclerosis:
Three-year analysis demonstrates continued robust treatment effect of Alemtuzumab compared to Rebif®

October 01, 2007 Age-related Macular Degeneration (AMD):
Bayer HealthCare Announces Positive Phase 2 Results for the VEGF Trap-Eye
Data presented at the Retina Society Conference in Boston

September 26, 2007 **Bayer Schering Pharma AG, Germany, and Genzyme Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis**

September 26, 2007 **Bayer MaterialScience to build a world-scale plant for polymer polyols in Antwerp**
- Total investment of around EUR 40 million
- Commissioning scheduled for late 2008
- Efficient production process delivers optimized products

September 25, 2007 **September 26, 2007: Last trading day for Bayer ADSs on Wall Street**

September 21, 2007 Hepatocellular carcinoma:
Nexavar® Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Treatment of Liver Cancer

September 20, 2007 B-cell chronic lymphocytic leukemia:
FDA Approves Expanded Labeling for Campath® to Include First-line Treatment for Leading Form of Adult Leukemia
Study data demonstrated improved progression-free survival with Campath

September 14, 2007 **Bayer completes acquisition of U.S. biologics manufacturing facility from Novartis**

September 13, 2007 **FDA Advisory Committees Recommend Continued US Marketing Authorization for Trasylol**
Committees also recommend further changes to US Label for Trasylol and additional safety studies

September 12, 2007 **Bayer MaterialScience examines feasibility of 400,000-ton MDI plant in Europe**
- Total worldwide capacity would increase to 1,850,000 tons a year
- Commissioning could take place in 2012

September 06, 2007 Bayer CropScience CEO Professor Friedrich Berschauer:
"Innovation and new technologies will help us to meet the growing demand for food and energy-producing plants"
- Stronger research focus on the needs of the "new ag economy"
- Promising active ingredient and plant biotechnology pipeline
- Seed and biotech sales to reach EUR 1 billion in the longer term
- Successful first half of 2007 indicates optimistic outlook for the full year

September 05, 2007 **Bayer intends to delist from the New York Stock Exchange**
- Purpose is to reduce complexity and costs
- Transparent financial reporting will continue

September 04, 2007 **New insecticidal active ingredient flubendiamide granted regulatory approval in major Asian markets**
Product launch strengthens Bayer CropScience's portfolio in the region

August 30, 2007 **Bayer HealthCare Strengthens US Consumer Health Business with Acquisition of Citracal®**
Addition of Leading Calcium Brand Enriches Consumer Care Division's Key Nutritionals Product Portfolio

August 27, 2007 **Bayer MaterialScience is to transfer EXATEC shares to GE Plastics**

August 27, 2007 **Nexavar Significantly Improved Overall Survival in Phase III Asia-Pacific Liver Cancer Trial**
Trial to be Stopped Early to Allow All Patients Access to Nexavar

August 21, 2007 **Medtronic and Bayer HealthCare announce alliance to provide blood glucose meter to Medtronic patients outside the United States**
New blood glucose meter to provide advanced therapy options for people with diabetes beginning in Canada and Europe

August 15, 2007 **Novel herbicidal active ingredient pyrasulfotole granted first regulatory approval**
Bayer CropScience to launch new cereal herbicide Huskie® in the United States in 2008

August 07, 2007 Gratifying trend in the second quarter of 2007
Bayer continues on a path of growth
- Sales up 22 percent to EUR 8,217 (6,736) million
- Underlying EBITDA climbs 39 percent to EUR 1,806 (1,303) million
- Underlying EBIT rises 30 percent to EUR 1,185 (911) million
- Net income advances by 46 percent to EUR 660 (452) million
- Underlying EBITDA margin above 20 percent expected for the full year

August 06, 2007 **Bayer HealthCare and Nektar Therapeutics To Develop Innovative Therapy For Pneumonia**

August 03, 2007 **Bayer HealthCare and Regeneron initiate Phase 3 global development program for VEGF Trap-Eye in wet age-related macular degeneration (AMD)**
Study will compare the VEGF Trap-Eye to ranibizumab (Lucentis®)

July 12, 2007 **YAZ® approved in the Netherlands as European Reference Member State**

July 08, 2007 **Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery**
Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor, Shows a Significant Reduction in Deep Vein Thrombosis and Pulmonary Embolism Compared with Enoxaparin with Similarly Low Bleeding Rates

July 02, 2007 **Bayer MaterialScience completes Taiwan Ure-Tech acquisition**
Aiming to be the global number one in thermoplastic polyurethanes (TPU)

July 02, 2007 **Dow Acquires Wolff Walsrode from Bayer**
Dow Secures Application Expertise and Broader Cellulosics Offering for End-use Segments

June 27, 2007 **Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer**
Nexavar is First Drug Therapy to Demonstrate Significant Survival Benefit in Liver Cancer

June 20, 2007 **Bayer CropScience and Monsanto enter long-term business and license agreements for key enabling technologies**
Agreements aim at creating new choices and more options for farmers

June 19, 2007 **Bayer CropScience completes acquisition of US cotton seed company Stoneville**

June 19, 2007 Bayer HealthCare Investor Day 2007:
Bayer raises guidance for 2007 and 2009
- Underlying EBITDA margin of the Bayer Group to exceed 22 percent by 2009
- Improved earnings forecast for Bayer HealthCare
- Integration of Bayer Schering Pharma proceeding more quickly than planned
- New research strategy adopted and pharmaceutical pipeline optimized
- Current clinical studies confirm the potential of rivaroxaban
- Nexavar® submitted in HCC
- New drug to control bleeding during surgery in licensed

June 04, 2007 **Bayer Schering Pharma AG will terminate registration with the U.S. SEC**

June 04, 2007 **Phase 3 Study: Nexavar® Significantly Extends Overall Survival by 44% in Liver Cancer Patients**
First Agent Ever to Demonstrate Significant Survival Benefit in Liver Cancer

May 31, 2007 **Bayer CropScience agrees to acquire US cotton seed company Stoneville for US-\$ 310 million**
Acquisition of leading US cotton business expected to bolster growth strategy

May 24, 2007 Annual Stockholders' Meeting of Bayer Schering Pharma AG, Berlin, Germany:
Integration of Bayer Schering Pharma progressing rapidly
- Positive business performance in the first quarter of 2007
- Domination and profit-and-loss transfer agreement confirmed

May 09, 2007 **Bayer MaterialScience expands production capacities in Shanghai for coating and adhesive raw materials**
New plant for polyurethane dispersions / Polyisocyanate production to be expanded

May 08, 2007 **Bayer publishes interim report for the first quarter of 2007**

May 03, 2007 **Bayer Schering Pharma, Berlin, Germany, prevails in litigation over domination agreement**

May 01, 2007 First-of-its-Kind Data Show:
Immediate Treatment of Early MS Patients with Betaferon® Significantly Delayed Permanent Disability
Risk to confirmed EDSS progression reduced by 40 percent compared to delayed treatment

April 27, 2007 Werner Wenning at the Annual Stockholders' Meeting in Cologne:
Bayer off to an excellent start in 2007
- Preliminary figures show substantial growth in first-quarter sales and earnings
- Positive outlook for full year confirmed
- Elections to the Supervisory Board

April 26, 2007 **Bayer exceeds consensus estimates for the first quarter of 2007**
- Preliminary figures show sales up 23 percent to EUR 8.3 billion
- Underlying EBITDA climbs 27 percent to EUR 2.0 billion
- Net income of EUR 2.8 billion including divestment proceeds
- Positive outlook for full year 2007 confirmed

April 18, 2007 **Novel cholesterol uptake inhibitor ZETIA® approved in Japan**
Product will be co-marketed by Bayer Yakuhin Ltd. and Schering-Plough K.K.

April 04, 2007 **Genzyme Files for Expanded Label for Campath® as First-Line Treatment for B-CLL Patients**

March 28, 2007 Bayer CropScience aims to grow in China:
Sales in the People's Republic forecast to top EUR 100 million in the medium term
Plans for two joint ventures for hybrid rice business and expansion of crop protection production

March 27, 2007 **Positive interim Phase 2 Data reported for VEGF Trap-Eye in age-related macular degeneration**
Bayer HealthCare and Regeneron plan to begin Phase 3 program in 2nd half of 2007

March 26, 2007 **Bayer deal with Novartis improves profit outlook for Betaseron® franchise**
- Bayer Schering Pharma AG, Germany, acquires U.S. Biologics manufacturing facility from Novartis
- Bayer will stop paying Novartis current royalty on Betaseron® from October 2008
- Bayer will provide licensing rights to Novartis to establish its own brand of interferon beta-1b from 2009 forward

March 15, 2007 Werner Wenning at the Spring Financial News Conference on March 15
2006 a record year for Bayer
- Sales up 17.2% to EUR 28,956 million
- EBITDA before special items climbs 21.3% to EUR 5,584 million
- EBIT before special items advances 14.2% to EUR 3,479 million
- Sales and underlying EBITDA expected to grow more than 10% in 2007
- Bayer Group targets underlying EBITDA margin of about 22% for 2009
- Bayer HealthCare aims for an underlying EBITDA margin of some 27% in 2009

March 15, 2007 **Supervisory Board of Bayer AG proposes stockholders' representatives for new term of office**

March 12, 2007 **Bayer increases dividend to EUR 1.00**
Total dividend payout rises 10.1 percent to EUR 764 million

March 02, 2007 **Bayer HealthCare announces concrete plans for the global synergy goals and job cuts**
- Savings in the order of EUR 700 million annually from 2009
- 6,100 jobs to be cut globally, 1,500 of these in Germany
- Headquarters in Berlin to remain the largest global location of Bayer Schering Pharma AG, Germany

March 01, 2007 **Bayer MaterialScience raises prices for Apec®, Makrolon®, Bayblend® and Makroblend® polycarbonates**

February 23, 2007 **Dr. Axel Steiger-Bagel appointed Chief Administration Officer of Bayer MaterialScience AG**

February 20, 2007 **Bayer HealthCare strengthens presence in Eastern Europe**
More than 200 staff for Marketing and Sales integrated in Russia, Belarus, the Ukraine and Kazakhstan

February 12, 2007 **New organizational structure to strengthen Bayer MaterialScience business**
Business Unit Heads to become members of Executive Committee

February 12, 2007 **Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer**
Trial To Be Stopped Early Based on Positive Outcome

February 08, 2007 **EU-Approval for Continuous Infusion of KOGENATE® Bayer**
Excellent Hemostatic Control Achieved

February 06, 2007 **Bayer Responds to study and commentary published in Journal of American Medical Association (JAMA)**

February 06, 2007 **Bayer MaterialScience intends to expand annual capacity of TDI production facility in Shanghai to 300,000 tons**
Innovative production technology means much lower costs

February 01, 2007 **Bayer HealthCare and CSL Behring Extend Agreement for Supply of Recombinant Factor VIII**
Global distribution deal extended through 2017

February 01, 2007 **Bayer completes sale of H.C. Starck to Advent International and The Carlyle Group**

January 30, 2007 **Innovative Long-Acting Contraceptive Product Mirena® approved in Japan**

January 29, 2007 **New indication for YAZ® approved in the U.S.**

January 26, 2007 **Oral formulation of Fludara® approved in Japan**

January 25, 2007 **Bayer discontinues Trasylol® clinical trial program in non-CABG indications**
Recent label changes for Trasylol® in CABG indication impact the clinical trial development in other indications

January 24, 2007 New active ingredient controls weeds in corn
Tembotrione given first regulatory approval
Bayer CropScience launches herbicide Laudis® in Austria, its first market

January 18, 2007 Extraordinary Stockholders' Meeting in Berlin
Squeeze-out to be implemented at Bayer Schering Pharma

January 17, 2007 Extraordinary Stockholders' Meeting in Berlin
Decision imminent on squeeze-out at Bayer Schering Pharma
- Proposed cash compensation of EUR 98.98 per Bayer Schering Pharma share
- Integration process making good headway

January 17, 2007 **Andreas Busch and Kemal Malik appointed to the Board of Management of Bayer Schering Pharma**
Marc Rubin, Board member for R&D, resigns his position

January 03, 2007 **Divestment of Bayer's diagnostics business to Siemens completed**

January 03, 2007 **Bayer MaterialScience lifts TDI Force Majeure**